Should prostate-specific antigen screening be offered to asymptomatic men?

Expert Review of Anticancer Therapy
Heidi A van VugtMonique J Roobol

Abstract

The benefits of population-based prostate cancer screening are the detection of clinically important prostate cancers at an early, still curable, stage and the subsequent reduction of prostate cancer-specific mortality. However, a prostate-specific antigen (PSA)-based prostate cancer screening program is currently insufficient to warrant its introduction as a public health policy. The main reasons are insufficient knowledge regarding the optimal screening strategy and overdiagnosis and overtreatment of indolent prostate cancers that are unlikely to lead to complaints or death. In some countries, guidelines have been developed on screening for prostate cancer, but the diversity of recommendations illustrates the limited knowledge on the optimal strategy. Therefore, men should be well informed about the benefits and potential harms of PSA screening in order to enable them to make an informed decision. Although a mortality reduction can be achieved by early detection of prostate cancer, patients and physicians must be aware of the current side effects of screening. Algorithms that advise screening at a young age (<55 years), with screening intervals of less than 4 years and low PSA thresholds (<3 ng/ml) for prostate biopsy seem pr...Continue Reading

References

Oct 8, 1987·The New England Journal of Medicine·T A StameyE Redwine
Feb 2, 1994·JAMA : the Journal of the American Medical Association·J I EpsteinC B Brendler
May 22, 2002·Cancer Causes & Control : CCC·Anssi AuvinenMatti Hakama
Jul 4, 2002·Journal of the National Cancer Institute·Ruth EtzioniEric J Feuer
Sep 13, 2002·The New England Journal of Medicine·Gunnar SteineckUNKNOWN Scandinavian Prostatic Cancer Group Study Number 4
Jun 26, 2003·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman
May 28, 2004·The New England Journal of Medicine·Ian M ThompsonCharles A Coltman
Oct 21, 2004·Cancer·David G BostwickBarry Timms
Feb 19, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P Boyle, J Ferlay
Apr 1, 2005·International Journal of Cancer. Journal International Du Cancer·Ida J KorfageHarry J de Koning
Jul 7, 2005·JAMA : the Journal of the American Medical Association·Ian M ThompsonCharles A Coltman
Dec 6, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ida J KorfageMarie-Louise Essink-Bot
Apr 20, 2006·Journal of the National Cancer Institute·Ian M ThompsonCharles A Coltman
Aug 17, 2006·Journal of the National Cancer Institute·Ian M ThompsonCharles A Coltman
Dec 13, 2006·The Journal of Urology·E W SteyerbergF H Schröder
Feb 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans LiljaGöran Berglund
Feb 9, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J FerlayP Boyle
Mar 3, 2007·World Journal of Urology·Felix K-H ChunMarkus Graefen
Mar 8, 2007·World Journal of Urology·Bob Djavan, Markus Margreiter
Apr 18, 2007·The Journal of Urology·Ian M ThompsonCharles A Coltman
May 29, 2007·European Urology·Roderick C N van den BerghChris H Bangma
Jul 17, 2007·The Journal of Urology·David M LatiniUNKNOWN CaPSURE Investigators
Jul 24, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sigrid CarlssonJonas Hugosson
Nov 13, 2007·European Urology·Fritz H SchröderMonique J Roobol
Dec 26, 2007·Urology·Onisuru T OkotieWilliam J Catalona
Feb 20, 2008·Prostate Cancer and Prostatic Diseases·D KaranD Lubaroff
Mar 21, 2008·The New England Journal of Medicine·Martin G SandaJohn T Wei

❮ Previous
Next ❯

Citations

Feb 8, 2011·Asian Journal of Andrology·Lionne D F Venderbos, Monique J Roobol
Nov 4, 2011·The Oncologist·Oliver SartorJohann Sebastian de Bono
Jul 28, 2011·Cancer Management and Research·Mohammad Kazem MoslemiSeyed Ali Tahvildar

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
David ConnollyLiam J Murray
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
Signe Benzon LarsenSusanne Oksbjerg Dalton
Current Oncology Reports
Elise D Cook, Ana C Nelson
Hematology/oncology Clinics of North America
Tudor BorzaAdam S Kibel
© 2021 Meta ULC. All rights reserved